Modeling disease with human pluripotent stem cells (hPSCs) is hindered because the impact on cell phenotype from genetic variability between individuals can be greater than from the pathogenic mutation. While “footprint-free” Cas9/CRISPR editing solves this issue, existing approaches are inefficient or lengthy. In this study, a simplified PiggyBac strategy shortened hPSC editing by 2 weeks and required one round of clonal expansion and genotyping rather than two, with similar efficiencies to the longer conventional process. Success was shown across four cardiac-associated loci (ADRB2, GRK5, RYR2, and ACTC1) by genomic cleavage and editing efficiencies of 8%–93% and 8%–67%, respectively, including mono- and/or biallelic events. Pluripotency was retained, as was differentiation into high-purity cardiomyocytes (CMs; 88%–99%). Using the GRK5 isogenic lines as an exemplar, chronic stimulation with the β-adrenoceptor agonist, isoprenaline, reduced beat rate in hPSC-CMs expressing GRK5-Q41 but not GRK5-L41; this was reversed by the β-blocker, propranolol. This shortened, footprint-free approach will be useful for mechanistic studies.
Get full access to this article
View all access options for this article.
References
1.
DenningC, BorgdorffV, CrutchleyJ, FirthKSA, GeorgeV, KalraS, KondrashovA, HoangMD, MosqueiraD, et al. (2016). Cardiomyocytes from human pluripotent stem cells: from laboratory curiosity to industrial biomedical platform. Biochim Biophys Acta, 1863:1728–1748.
2.
SmithJG, CelizAD, PatelAK, ShortRD, AlexanderMR and DenningC. (2015). Scaling human pluripotent stem cell expansion and differentiation: are cell factories becoming a reality?. Regen Med, 10:925–930.
3.
SalaL, BellinM and MummeryCL. (2016). Integrating cardiomyocytes from human pluripotent stem cells in safety pharmacology: has the time come?. Br J Pharmacol, 174:3749–3765.
4.
KimHS, LeeK, BaeS, ParkJ, LeeCK, KimM, KimE, KimS, KimC and KimJS. (2017). CRISPR/Cas9-mediated gene knockout screens and target identification via whole-genome sequencing uncover host genes required for picornavirus infection. J Biol Chem, 292:10664–10671.
5.
MeierID, BernreutherC, TillingT, NeidhardtJ, WongYW, SchulzeC, StreichertT and SchachnerM. (2010). Short DNA sequences inserted for gene targeting can accidentally interfere with off-target gene expression. FASEB J, 24:1714–1724.
6.
PanY, ZhangL, LiuQ, LiY, GuoH, PengY, PengH, TangB, HuZ, et al. (2016). Insertion of a knockout-first cassette in Ampd1 gene leads to neonatal death by disruption of neighboring genes expression. Sci Rep, 6:35970.
7.
KimS, KimD, ChoSW, KimJ and KimJS. (2014). Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res, 24:1012–1019.
8.
DeWittMA, MagisW, BrayNL, WangT, BermanJR, UrbinatiF, HeoSJ, MitrosT, MuñozDP, et al. (2016). Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells. Sci Transl Med, 8:360ra134.
9.
PaquetD, KwartD, ChenA, SproulA, JacobS, TeoS, OlsenKM, GreggA, NoggleS, Tessier-LavigneM. (2016). Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. Nature, 533:125–129.
10.
YusaK. (2013). Seamless genome editing in human pluripotent stem cells using custom endonuclease-based gene targeting and the piggyBac transposon. Nat Protoc, 8:2061–2078.
11.
YusaK, RashidST, Strick-MarchandH, VarelaI, LiuPQ, PaschonDE, MirandaE, OrdóñezA, HannanNR, et al. (2011). Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Nature, 478:391–394.
12.
SunN and ZhaoHM. (2014). Seamless Correction of the Sickle Cell Disease Mutation of the HBB Gene in Human Induced Pluripotent Stem Cells Using TALENs. Biotechnol Bioeng, 111:1048–1053.
13.
XieF, YeL, ChangJC, BeyerAI, WangJM, MuenchMO and KanYW. (2014). Seamless gene correction of beta-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Res, 24:1526–1533.
14.
AmpsK, AndrewsPW, AnyfantisG, ArmstrongL, AveryS, BaharvandH, BakerJ, BakerD, MunozMB, et al. (2011). Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol, 29:1132–1144.
15.
AllegrucciC, WuYZ, ThurstonA, DenningCN, PriddleH, MummeryCL, Ward-van OostwaardD, AndrewsPW, StojkovicM, et al. (2007). Restriction landmark genome scanning identifies culture-induced DNA methylation instability in the human embryonic stem cell epigenome. Hum Mol Genet, 16:1253–1268.
16.
AllegrucciC and YoungLE. (2007). Differences between human embryonic stem cell lines. Hum Reprod Update, 13:103–120.
17.
BosmanA, LetourneauA, SartianiL, Del LungoM, RonzoniF, KuziakivR, TohonenV, ZucchelliM, SantoniF, et al. (2015). Perturbations of heart development and function in cardiomyocytes from human embryonic stem cells with trisomy 21. Stem Cells, 33:1434–1446.
18.
LiuP, KaplanA, YuanB, HannaJH, LupskiJR and ReinerO. (2014). Passage number is a major contributor to genomic structural variations in mouse iPSCs. Stem Cells, 32:2657–2667.
19.
WangG, YangL, GrishinD, RiosX, YeLY, HuY, LiK, ZhangD, ChurchGM and PuWT. (2017). Efficient, footprint-free human iPSC genome editing by consolidation of Cas9/CRISPR and piggyBac technologies. Nat Protoc, 12:88–103.
20.
BurridgePW, AndersonD, PriddleH, MunozMDB, ChamberlainS, AllegrucciC, YoungLE and DenningC. (2007). Improved human embryonic stem cell embryoid body homogeneity and cardiomyocyte differentiation from a novel V-96 plate aggregation system highlights interline variability. Stem Cells, 25:929–938.
21.
SotoodehniaN, SiscovickDS, VattaM, PsatyBM, TracyRP, TowbinJA, LemaitreRN, ReaTD, DurdaJP, et al. (2006). Beta2-adrenergic receptor genetic variants and risk of sudden cardiac death. Circulation, 113:1842–1848.
22.
DaerRM, CuttsJP, BrafmanDA and HaynesKA. (2017). The impact of chromatin dynamics on Cas9-mediated genome editing in human cells. ACS Synth Biol, 6:428–438.
23.
DrysdaleCM, McGrawDW, StackCB, StephensJC, JudsonRS, NandabalanK, ArnoldK, RuanoG and LiggettSB. (2000). Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A, 97:10483–10488.
24.
ParolaAL and KobilkaBK. (1994). The peptide product of a 5′ leader cistron in the beta 2 adrenergic receptor mRNA inhibits receptor synthesis. J Biol Chem, 269:4497–4505.
25.
TholanikunnelBG, JosephK, KandasamyK, BaldysA, RaymondJR, LuttrellLM, McDermottPJ and FernandesDJ. (2010). Novel mechanisms in the regulation of G protein-coupled receptor trafficking to the plasma membrane. J Biol Chem, 285:33816–33825.
26.
KarlinS, BurgeC, CampbellAM. (1992). Statistical analyses of counts and distributions of restriction sites in DNA sequences. Nucleic Acids Res, 20:1363–1370
27.
GalvanDL, NakazawaY, KajaA, KettlunC, CooperLJ, RooneyCM and MHWilson. (2009). Genome-wide mapping of PiggyBac transposon integrations in primary human T cells. J Immunother, 32:837–844.
28.
LiggettSB, CresciS, KellyRJ, SyedFM, MatkovichSJ, HahnHS, DiwanA, MartiniJS, SparksL, et al. (2008). A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med, 14:510–517.
29.
SongW, DyerE, StuckeyDJ, CopelandO, LeungMC, BaylissC, MesserA, WilkinsonR, TremoledaJL, et al. (2011). Molecular mechanism of the E99K mutation in cardiac actin (ACTC Gene) that causes apical hypertrophy in man and mouse. J Biol Chem, 286:27582–27593.
30.
BarbantiC, MaltretA and SidiD. (2017). A focus on pharmacological management of catecholaminergic polymorphic ventricular tachycardia. Mini Rev Med Chem. [Epub ahead of print];, DOI: 10.2174/1389557517666170707100923.
31.
BraamSR, TertoolenL, CasiniS, MatsaE, LuHR, TeismanA, PassierR, DenningC, GallacherDJ, TowartR and MummeryCL. (2013). Repolarization reserve determines drug responses in human pluripotent stem cell derived cardiomyocytes. Stem Cell Res, 10:48–56.
32.
MoritaH, WuJ and ZipesDP. (2008). The QT syndromes: long and short. Lancet, 372:750–763.
33.
ChristT, HorvathA and EschenhagenT. (2015). LQT1-phenotypes in hiPSC: are we measuring the right thing?. Proc Natl Acad Sci U S A, 112:E1968.
34.
GreberB, VerkerkAO, SeebohmG, MummeryCL and Bellin.M (2015). Reply to Christ et al.: LQT1 and JLNS phenotypes in hiPSC-derived cardiomyocytes are due to KCNQ1 mutations. Proc Natl Acad Sci U S A, 112:E1969.
35.
ShenH, LiJ, ZhangJ, XuC, JiangY, WuZ, ZhaoF, LiaoL, ChenJ, et al. (2013). Comprehensive characterization of human genome variation by high coverage whole-genome sequencing of forty four Caucasians. PLoS One, 8:e59494.
BellinM, CasiniS, DavisRP, D'AnielloC, HaasJ, Ward-van OostwaardD, TertoolenLG, JungCB, ElliottDA, et al. (2013). Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome. EMBO J, 32:3161–3175.
38.
ZhangM, D'AnielloC, VerkerkAO, WrobelE, FrankS, Ward-van OostwaardD, PicciniI, FreundC, RaoJ, et al. (2014). Recessive cardiac phenotypes in induced pluripotent stem cell models of Jervell and Lange-Nielsen syndrome: disease mechanisms and pharmacological rescue. Proc Natl Acad Sci U S A, 111:E5383–E5392.
39.
LiewCG, DraperJS, WalshJ, MooreH and AndrewsPW. (2007). Transient and stable transgene expression in human embryonic stem cells. Stem Cells, 25:1521–1528.
40.
AndersonD, SelfT, MellorIR, GohG, HillSJ and DenningC. (2007). Transgenic enrichment of cardiomyocytes from human embryonic stem cells. Mol Ther, 15:2027–2036.
41.
NorrmanK, FischerY, BonnamyB, Wolfhagen SandF, RavassardP and SembH. (2010). Quantitative comparison of constitutive promoters in human ES cells. PLoS One, 5:e12413.
42.
DengC and CapecchiMR. (1992). Reexamination of gene targeting frequency as a function of the extent of homology between the targeting vector and the target locus. Mol Cell Biol, 12:3365–3371.
43.
KanY, RuisB, TakasugiT and HendricksonEA. (2017). Mechanisms of precise genome editing using oligonucleotide donors. Genome Res, 2017;27:1099–1111.
44.
DavisL and MaizelsN. (2016). Two distinct pathways support gene correction by single-stranded donors at DNA nicks. Cell Rep, 2016;17:1872–1881.
45.
KanY, RuisB, LinS and EAHendrickson. (2014). The mechanism of gene targeting in human somatic cells. PLoS Genet, 2014;10:e1004251.
46.
OlariuV, HarrisonNJ, CocaD, GokhalePJ, BakerD, BillingsS, KadirkamanathanV and AndrewsPW. (2010). Modeling the evolution of culture-adapted human embryonic stem cells. Stem Cell Res, 4:50–56.
47.
AndrewsPW, BakerD, BenvinistyN, MirandaB, BruceK, BrüstleO, ChoiM, ChoiYM, CrookJM, et al. (2015). Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI). Regen Med, 2015;10,(2 Suppl)::1–44.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
